haematology
Bleeding disorders

No need to stop ibrutinib in patients who develop AF


Atrial fibrillation related to ibrutinib treatment can be managed with standard measures  and DOACs without patients having to stop cancer treatment, experience at an Australian centre suggests. Ibrutinib-related AF was more common in real world practice than in the literature, according to a small cohort report by haematologists at the Hunter New England Health District. ...

Already a member?

Enter your email to keep reading.


OR